Newborn Hep B Vaccine Vote Postponed — ACIP Retreats, Leaving Questions Hanging

The committee guiding U.S. vaccine policy quietly pushed off a pivotal decision today. The Advisory Committee on Immunization Practices (ACIP) voted 7-3 to delay until tomorrow whether to overturn the long-standing recommendation that all newborns receive the Hepatitis B vaccine within 12–24 hours after birth.

A Shift in the Air — What’s Under Debate

The motion up for reconsideration hinges on language that, if approved, would significantly change the birth-dose policy. For babies born to mothers who test negative for hepatitis B — more than 99.5% of infants — the decision to vaccinate at birth would no longer be automatic. Instead, parents, together with their healthcare provider, would choose if and when to vaccinate.

Under the new proposal:

Those newborns would get their first Hep B vaccine no earlier than around two months of age.
For infants whose mothers are hepatitis positive or whose status is unknown, the birth-dose recommendation stays.
A third layer would ask providers to possibly run antibody testing (serology) before giving subsequent doses — potentially skipping them if immunity is already present. Children’s Health Defense

Importantly, the revisions, if passed, would not change whether insurance or programs like Medicaid cover the vaccine for those who choose it.

What’s Changed — And Why This Matters

This isn’t the first time the birth-dose timing has been questioned. But what’s on the table now goes deeper than a simple one-month delay.

At the heart of today’s clash: some ACIP members argue there’s no evidence of harm from the early dose and see no compelling reason to alter decades-old policy.Others counter sharply — saying there is equally no proof of long-term safety, especially given that early clinical trials lacked rigorous placebos and extended follow-up for newborns.

Help keep this independent voice alive and uncensored. Buy us a Coffee

As one critic put it: We’re not asking “Is this harmful?” but “Can we confidently say it’s safe beyond any doubt?”

To some observers, this debate marks the most controversial shift yet under the committee’s new leadership — chosen earlier this year by Robert F. Kennedy Jr..

What Comes Next

The vote is rescheduled for tomorrow. But the stakes go beyond a single vaccine decision.

Over the next two days, the committee plans to dig into the entire childhood immunization schedule — and raise fresh concerns about vaccine components such as aluminum, long used as an adjuvant.

Speakers scheduled to testify include individuals with backgrounds not in traditional epidemiology — a move that many experts say signals a deeper realignment of how the U.S. assesses public health policy.

Whether this marks the start of a broad re-writing of immunization norms — or a temporary pause — remains unclear. For now, what’s certain is that the quiet halls of policy deliberation have opened a door to debate that many thought long settled.

Chris Wick